Acceleron: When Bad News Is Really Good News By: Stocks to Watch June 13, 2017 at 10:02 AM EDT Acceleron has discontinued development of a kidney cancer after it failed in a clinical trial. Yet the drug maker's stock is on the rise today. Here's why. Read More >>